ABIVAX Stock: Shares Fall 5.74% Over the Past Week
ABIVAX stock closed at €115.00 on Friday, marking a 5.74% decline for the week of December 24 to January 2. This trend contrasts with the positive performance of the SBF 120, which increased by 1.14% during the same period. Despite this recent downturn, the stock maintains an impressive annual performance of 1,601%.
Weekly Performance Overview
Over the past week, ABIVAX's share price followed a downward trajectory, closing at €115.00 on Friday, January 2, down from €122.00 on the previous December 24. The weekly change amounted to -5.74%, a movement in contrast to the moderate rises in the CAC 40 (+1.13%) and SBF 120 (+1.14%). Trading was particularly brisk mid-week: December 29 saw a volume of 197,523 shares, followed by 85,179 on December 30, while volumes were more moderate on other days, with 66,781 shares on January 2 and 50,046 on December 24. The stock reached a weekly high of €128.40 on December 29, before falling to a low of €114.20 the same day, showing significant volatility with a monthly standard deviation of 25.91%. In the long term, the performance remains exceptional: +1,601% over one year, +1,651% over six months, and +222% over five years, placing ABIVAX among the top gainers in the SBF 120 in 2025, with an annual increase highlighted at over 1,600%. Analyst consensus points to a three-month target price of €120.47, representing a potential of 1.58% relative to the recent close. The particularly low beta of 0.01 indicates a weak correlation with the overall market, reinforcing the specific profile of this biopharmaceutical value. These technical and fundamental elements frame a week of correction after recent peaks around €128.
Technical Analysis Insights
Technical analysis reveals an intermediate positioning for the stock. The 50-day moving average is at €99.19, while the 200-day average stands at €49.66, with the current price of €115.00 significantly above both benchmarks. The upper Bollinger Band reaches €128.16 and the lower band at €86.79, thus framing the recent fluctuations around the resistance threshold of €122.40 and the support at €93.30. The MACD indicator displays a line at 4.93, and the RSI stabilizes at 50, signaling a balance without excessive selling or buying. The 20-day moving average, estimated at around €107.50 based on recent data, also supports the underlying bullish trend. These technical levels depict a scenario where the stock oscillates in a neutral zone in the short term, after testing the week's highs. The recent absolute high at €128.40 contrasts with the weekly low at €114.20, confirming high volatility compatible with the biotech sector. On Euronext Paris, daily trading shows alternating daily changes: +0.33% on December 29 at €122.40, -5.23% on December 30 at €116.00, +3.79% on December 31 at €120.40, and -4.32% on January 2 at €115.20 during the session, before stabilizing at €115.00 at close. These fluctuations occur in a context of variable volumes, with a peak of 197,523 shares on December 29. On a broader scale, historical performances reinforce resilience: +62.59% over three months and +8.85% over one month, despite the weekly decline. Analyst forecasts for 2025 and 2026 indicate an estimated net earnings per share of -€3.06 and -€2.99 respectively, with no dividend.
